APA (7th ed.) Citation

Petrioli, R., Chirra, M., Messuti, L., Fiaschi, A. I., Savelli, V., Martellucci, I., & Francini, E. (2018). Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. Clinical colorectal cancer, 17(4), 307-312. https://doi.org/10.1016/j.clcc.2018.02.005

Chicago Style (17th ed.) Citation

Petrioli, Roberto, Martina Chirra, Luciana Messuti, Anna Ida Fiaschi, Vinno Savelli, Ignazio Martellucci, and Edoardo Francini. "Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy." Clinical Colorectal Cancer 17, no. 4 (2018): 307-312. https://doi.org/10.1016/j.clcc.2018.02.005.

MLA (9th ed.) Citation

Petrioli, Roberto, et al. "Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy." Clinical Colorectal Cancer, vol. 17, no. 4, 2018, pp. 307-312, https://doi.org/10.1016/j.clcc.2018.02.005.